An interventional study of Patient decision aid to support shared decision-making between patients and clinicians in Acute Coronary Syndrome, sponsored by Montreal Heart Institute. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Montreal Heart Institute · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Acute Coronary Syndrome with a site in Canada — 9 open to participants now, 13 under way, 4 of them phase 3. Acute Coronary Syndrome · Canada.
Among the 104 studies in Acute Coronary Syndrome with a site in Canada, this one is the 88th largest by enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2026, is one of 27 with no phase, and was the 101st registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →9 of the 104 studies in Acute Coronary Syndrome with a site in Canada are open now. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+ · Healthy volunteers
DalCor Pharmaceuticals · Sites in Canada, United States, Puerto Rico
Ages 45+
St. Boniface Hospital · Sites in Canada
Ages 18–80
Sir Mortimer B. Davis - Jewish General Hospital · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 17 · Phase 3 34 · Phase 4 14
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 504 across the 90 interventional studies, 348 across the 14 observational. Of the 84 that completed or were terminated, 29 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 104 have an industry lead sponsor. The 10 most frequent:
Montreal Heart Institute is the lead sponsor of 101 studies on the registry; 23 are open to participants now.
Montreal Heart Institute has 4 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Acute Coronary Syndrome with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
| NCT05918861Phase 3DalCor PharmaceuticalsEffect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | 2027-08 |
| NCT07171580St. Boniface HospitalTailoring Post Discharge - Remote Education and Access for Cardiac Health | 2026-11-30 |
| NCT06091319Ottawa Heart Institute Research CorporationFlorbetaben for Imaging of Vascular Amyloid | 2026-12-01 |
| NCT07685639University of AlbertaElectronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 104 studies in Acute Coronary Syndrome with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Among patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and stent implantation, 17.5% are both at high bleeding risk (HBR) and have undergone complex PCI, which also places them at high thrombotic risk. In this population, several dual antiplatelet therapy (DAPT) strategies may be considered: (1) de-escalation of DAPT intensity after 1 to 3 months (switch from ticagrelor/prasugrel to clopidogrel), (2) shortening DAPT duration to 1 to 3 months followed by antiplatelet monotherapy, (3) 12-month clopidogrel-based DAPT, and (4) 12-month ticagrelor/prasugrel-based DAPT. Selecting the most appropriate DAPT strategy in this dual-risk context is complex, and clinical trial evidence is limited for this specific subgroup. In the absence of clear guideline recommendations to support decision-making for patients facing both elevated bleeding and thrombotic risks, structured shared decision-making support is needed.
In this context, within research project 2025-3499 conducted with pharmacy residents, we developed a patient decision aid (PDA) designed to support shared decision-making by helping patients understand their risks, available options, and potential consequences, so they can express their preferences regarding antiplatelet therapy. The PDA aims to facilitate shared decisions by improving patients' understanding of benefits and harms and aligning choices with patient values. A preliminary version of the tool has already undergone alpha testing with a small group of internal users (physicians, pharmacists, and patient partners). The next step is beta testing, that is, real-world testing with the target population and clinicians to evaluate usability and acceptability in routine practice.
Inclusion Criteria (Patients)
Inclusion Criteria (Clinicians)
- Clinicians working in the MHI coronary care unit (cardiologists, medical residents, nurse practitioners, or pharmacists) who use the patient decision aid with one or more study participants
Exclusion Criteria (Patients)
The intervention is the use of the Patient Decision Aid (PDA) to support shared decision-making between patients and clinicians after PCI, assessed using questionnaires capturing multiple dimensions of decision quality. No pharmacologic treatment is administered as part of the study; exposure consists solely of complete use of the PDA according to the protocol. The study includes a single pre-post group, no interim analyses are planned given the limited project duration, and a single beta-testing phase will be conducted.
Other: Patient decision aid to support shared decision-making between patients and clinicians
Patient decision aid to support shared decision-making between patients and clinicians by helping patients understand their risks, available options, and potential consequences, so they can express their preferences regarding antiplatelet therapy.
Change in Decisional Conflict (DCS-LL) After Use of the Patient Decision Aid (PDA)
Change in total score on the low-literacy Decisional Conflict Scale (DCS-LL; Ottawa Hospital Research Institute), comparing pre-PDA vs post-PDA completion. Lower scores indicate less decisional conflict.
Time frame: Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).
Change in Antiplatelet Strategy Knowledge Score After PDA Use
Change in total score on an adapted OHRI knowledge questionnaire assessing understanding of bleeding and thrombotic risks and DAPT options, comparing pre-PDA vs post-PDA completion.
Time frame: Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).
Preparation for Decision-Making (PrepDM) Score After PDA Use
Total score on the Preparation for Decision Making (PrepDM; OHRI) questionnaire completed after PDA use. Higher scores indicate greater perceived preparedness to make a decision with the clinician.
Time frame: Immediately post-PDA completion (Day 0, index hospitalization).
Patient Acceptability Score of the PDA in Routine Clinical Use
Total score on an OHRI acceptability questionnaire completed after PDA use, reflecting perceived relevance, clarity, length, and overall acceptability in the clinical setting.
Time frame: Immediately post-PDA completion (Day 0, index hospitalization).
Patient Refusal Rate to Use the PDA and Reasons for Refusal
Number and proportion of eligible patients who personally refuse participation/PDA use, and categorization of documented reasons for refusal (e.g., not interested, too tired, overwhelmed, language barriers, time constraints).
Time frame: Pre-intervention (at the time of the consent request, prior to PDA delivery, during the index hospitalization).
Agreement Between Patient-Preferred Antiplatelet Strategy and Strategy Prescribed at Hospital Discharge
Proportion of agreement between (a) the antiplatelet strategy preferred by the patient as identified through the PDA and (b) the antiplatelet strategy documented on the discharge prescription/orders.
Time frame: At hospital discharge (index hospitalization), comparing the patient preference recorded immediately after PDA completion with the antiplatelet strategy on the discharge prescription/orders (also post-PDA completion).
Clinician Usability of the PDA (French System Usability Scale, F-SUS)
Total score on the French System Usability Scale (F-SUS) completed by clinicians after using the PDA with an included patient in routine clinical care. Higher scores indicate better usability.
Time frame: Day 0 (immediately after PDA use with an included patient)
Clinician Refusal Rate to Use the PDA and Reasons for Non-Use
Number and proportion of eligible patient encounters in which the clinician declines to use the PDA when asked, along with categorization of documented reasons (e.g., time constraints, clinical instability, workflow barriers, clinician preference).
Time frame: Pre-intervention (at the time the clinician is asked whether it is appropriate to approach the patient and offer the PDA, prior to patient approach and prior to PDA delivery, during the index hospitalization).
Exploratory Subgroup Effects on Decisional Conflict Scores Low Litteracy (DCS-LL) Questionnaire
Exploratory assessment of whether changes in DCS-LL differ by prespecified characteristics: age (\<70 vs ≥70 years), sex (male vs female), mother tongue (French vs English), education level (university vs lower) and prior percutaneous intervention with stent (yes or no). Analyses are descriptive/exploratory.
Time frame: Baseline (pre-PDA, Day 0) and immediately post-PDA completion (Day 0, index hospitalization).
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in Sep 2026, 7 months.
Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's 7 months is below that.
Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Aug 2026 → Sep 2026 and completion Dec 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.